Concierge dermatology · London
Mole mapping and melanoma, the melanoma-focused surveillance package — mapping, excision, sentinel node and beyond.
A melanoma-focused surveillance package combining consultant dermatologist review, total-body mole mapping, dermoscopy, excision biopsy, sentinel-node biopsy referral and modern melanoma MDT-linked care.
Why patients choose us
- 01
The right hands
We route you to a consultant dermatologist with melanoma-specific expertise, working alongside a skin-cancer MDT — not a generalist.
- 02
End-to-end pathway
Mapping, dermoscopy, excision, sentinel-node planning and adjuvant care handled inside one coordinated pathway.
- 03
Independent, and free
We are paid by no clinic, so the recommendation is impartial and costs you nothing.
Indicative pricing
What a private melanoma pathway costs in London.
Indicative ranges across our partner clinics. Send the details and we quote firm figures across two or three options.
In short
Consultant review from £280, mapping from £450, with the surgical and oncology pathway coordinated end-to-end.
| Service | Indicative range | Typical duration | Report turnaround |
|---|---|---|---|
| Consultant dermatology review | £280–£450 | 30 min | Same visit |
| Total-body mole mapping (baseline) | £450–£900 | 45 min | 3–5 days |
| Excision biopsy of suspicious lesion | £550–£1,200 | 30–60 min | 7–10 days |
| Sentinel-node biopsy (surgical package) | £4,500–£8,500 | Day case | 10–14 days |
| Adjuvant immunotherapy cycle (indicative) | From £6,000 | Day unit | Per cycle |
| Structured surveillance package (annual) | £950–£1,600 | Half-day | 5 working days |
Prices vary by clinic, by the extent of surgery required, and by the adjuvant treatment chosen. We come back with a firm quote within one working day.
Key facts
What this package actually is.
Six things to know before deciding whether the full melanoma pathway is right for you — or whether a plain mole check or mole mapping is enough.
-
Definition
Integrated melanoma-focused surveillance and treatment package for people at higher risk.
-
Full team, one pathway
Mole mapping plus dermatology, surgery and oncology MDT under one roof.
-
Sentinel-node biopsy pathway
Planned staging surgery for confirmed invasive melanoma when indicated.
-
Modern adjuvant immunotherapy
Access to nivolumab and pembrolizumab where clinically appropriate.
-
Post-treatment surveillance imaging
Structured follow-up combining clinical review, mapping and cross-sectional imaging.
-
Genetic counselling
For hereditary melanoma risk — CDKN2A and related predispositions.
Diagnosis steps
From consultation to adjuvant plan — what happens, in order.
One coordinated pathway from dermatology to oncology MDT.
Phase 1 · Assessment
Consultation and baseline mapping
Phase 2 · Investigation
Dermoscopy and excision biopsy
Phase 3 · MDT and treatment
Staging, surgery and adjuvant care
- 01
Assessment
Dermatology consultation
Consultant dermatologist review — history, family history, sun-exposure profile, prior lesions.
- 02
Assessment
Total-body mole mapping
High-resolution total-body photography establishes a permanent baseline of every mole.
- 03
Investigation
Dermoscopy of high-risk lesions
Polarised dermoscopic imaging of any lesion that looks changed, atypical or new.
- 04
Investigation
Excision biopsy
Any suspicious lesion is excised with an appropriate margin and sent for histopathology.
- 05
MDT & treatment
Melanoma MDT
Confirmed melanoma is discussed at a skin-cancer multidisciplinary team meeting — surgery, oncology, radiology, pathology.
- 06
MDT & treatment
Sentinel-node biopsy planning
For invasive melanoma meeting criteria, sentinel-node biopsy is planned as a staging step.
- 07
MDT & treatment
Adjuvant therapy discussion
Oncology discusses adjuvant immunotherapy, targeted therapy, radiotherapy and surveillance.
Typical assessment to MDT: 2–3 weeks. Urgent suspicious lesions: days.
What it shows
The specific questions this package answers.
Mole mapping alone gives a baseline. The full pathway also tells you what a lesion is, how deep it goes, whether it has spread and how it should be treated.
-
Baseline mole distribution
A permanent, whole-body photographic baseline against which future change is judged.
-
New / changing melanoma
Detects new lesions and interval change on existing moles at the earliest possible stage.
-
In-situ vs invasive melanoma
Distinguishes melanoma in-situ from invasive disease on histopathology.
-
Breslow thickness and mitotic rate
Reports the histopathological features that drive staging and treatment.
-
Sentinel-node status
Confirms whether melanoma has spread to the first draining lymph node.
-
BRAF / NRAS mutation status
Molecular profiling that determines eligibility for targeted therapy.
-
Post-treatment surveillance findings
Interval change, scar recurrence and new primaries picked up on structured follow-up.
-
Red flag: metastatic melanoma — urgent oncology MDT
Any suggestion of distant spread is escalated immediately to the oncology MDT.
Treatment options
What treatment for melanoma looks like today.
Not every option is right for every case — the MDT decides. This is the modern menu.
-
Wide local excision
Definitive excision of the primary melanoma with a stage-appropriate margin.
-
Sentinel-node biopsy
Day-case surgical staging of the first draining lymph node for invasive melanoma.
-
Complete lymphadenectomy (selected)
Formal nodal clearance in selected node-positive cases where clinically indicated.
-
Adjuvant immunotherapy
Nivolumab or pembrolizumab after surgery to reduce the risk of recurrence in stage III disease.
-
Targeted BRAF/MEK therapy
Oral targeted therapy for BRAF-mutant melanoma in the adjuvant or metastatic setting.
-
Radiotherapy
Local or nodal radiotherapy in selected high-risk or symptomatic cases.
-
Structured surveillance
Serial photography, dermoscopy and cross-sectional imaging on a stage-appropriate schedule.
-
Genetic counselling (CDKN2A)
Formal genetics assessment for familial melanoma and CDKN2A carriers.
Our vetted London network
A small panel of clinics, we picked them.
Partners across central, north, west and south London. Not listed publicly — introductions are made privately, once we understand your case.
Selection criteria
How we choose every clinic in our network.
-
Consultant dermatologists with a melanoma-specific caseload
-
Total-body photography and polarised dermoscopy on modern hardware
-
Skin-cancer MDT with surgery, oncology, radiology and pathology
-
Access to sentinel-node biopsy and adjuvant immunotherapy
Red flags and higher-risk situations
When a routine slot isn’t enough.
Nine presentations that change the pathway — from urgent MDT escalation to formal genetic assessment.
-
Metastatic melanoma
Any suggestion of distant spread is a same-day oncology MDT referral, not a routine follow-up.
-
Multiple primary melanomas
Two or more primary melanomas raise the threshold for genetic testing and lifelong surveillance.
-
Family melanoma + pancreatic cancer (CDKN2A)
This cluster suggests hereditary melanoma-pancreatic-cancer syndrome — refer to clinical genetics.
-
Post-transplant melanoma
Immunosuppression changes both risk and management — coordinated with the transplant team.
-
Nail-bed / mucosal melanoma
Non-cutaneous melanoma behaves differently and needs specialist review from the outset.
-
Amelanotic melanoma
Pink or skin-coloured lesions can be melanoma — dermoscopy and low threshold for biopsy.
-
Post-op recurrence
Any new nodule at or near a prior excision scar is treated as recurrence until proven otherwise.
-
Central nervous system metastases
New neurology in a melanoma patient warrants urgent brain imaging and MDT.
-
Post-immunotherapy adverse events
Endocrine, hepatic, pulmonary or colitic symptoms after immunotherapy need urgent oncology review.
Reading your report
A dermatology and histopathology report can look intimidating. It isn’t.
Whatever the finding, the report keeps to the same four parts.
A quiet reminder
The report is written for your doctor, not for you — and that’s normal.
If you would like us to talk you through it before your follow-up, just ask.
- 01 Header
Indication and risk factors
Your details, the reason for review, and the risk factors that shape interpretation — family history, skin type, prior lesions.
- 02 Technique
Mapping and dermoscopy
What was photographed, at what resolution, and which lesions were dermoscopically imaged.
- 03 Findings
Lesion-by-lesion description
Each flagged lesion described with dermoscopic features, size, location and change from baseline.
- 04 Impression
The conclusion: read this first
Reassure, re-image, biopsy or refer — the concrete next step, up front.
Recognised by major UK insurers
Cover depends on your policy and clinic; we confirm with your insurer before booking.
Frequently asked
Everything we get asked about mole mapping and melanoma.
Quick answers on who this package is for, sentinel-node biopsy, adjuvant treatment and timelines.
-
What is the difference between a mole check, mole mapping and this package?
A mole check is a single consultant review of your skin. Mole mapping adds a permanent whole-body photographic baseline. This melanoma-focused package folds mapping into a full pathway — dermatology, excision, sentinel-node planning, MDT and adjuvant care — for people at higher risk or with a suspected or confirmed melanoma.
-
Who should consider a melanoma-focused package rather than mole mapping alone?
Anyone with a personal or strong family history of melanoma, multiple atypical naevi, prior non-melanoma skin cancer with concerning features, or a lesion already flagged as suspicious. If in doubt, we say so — sometimes plain mole mapping is enough.
-
What happens if a mole is suspicious?
It is excised with an appropriate margin and sent for histopathology. If melanoma is confirmed, your case goes to a skin-cancer MDT and, if indicated, on to sentinel-node biopsy and adjuvant discussion.
-
What is a sentinel-node biopsy and when is it needed?
It is a day-case surgical staging procedure that samples the first draining lymph node for microscopic spread. It is considered for invasive melanoma meeting thickness and other criteria — the MDT decides, not the scan alone.
-
What adjuvant treatments might be offered?
For stage III disease, adjuvant immunotherapy (nivolumab or pembrolizumab) is the modern standard. BRAF-mutant melanoma may also be treated with targeted BRAF/MEK therapy. Radiotherapy is reserved for selected cases.
-
How quickly can this be organised?
Initial dermatology and mapping is usually arranged within days. Excision biopsy typically within one to two weeks. If melanoma is confirmed, MDT and onward surgery happen on a defined cancer timeline — we coordinate the whole pathway.
Sources
- British Association of Dermatologists. Melanoma guidelines and patient information.
- NICE. Melanoma: assessment and management (NG14).
- European Society for Medical Oncology. Cutaneous melanoma clinical practice guidelines.
- Melanoma UK. Patient information and support.
Reviewed by Pulse Atlas Editorial Board, . Published 2026-07-30. Next review 2027-07-30. Estimated reading time 6 minutes.
Related tests
Looking for a different test?
-
Mole check
A single consultant dermatologist review of your skin.
Learn more -
Mole mapping
Total-body photographic baseline for surveillance.
Learn more -
Excisional biopsy
Definitive removal of a suspicious lesion for histology.
Learn more -
All tests
Browse every test and procedure we arrange.
Learn more -
Acne
Related condition guide.
Learn more -
Eczema
Related condition guide.
Learn more -
Cryotherapy Treatment
Related treatment option.
Learn more -
Curettage Cautery Lesions
Related treatment option.
Learn more
In practice, in London
The London pathway for mole mapping and melanoma
With mole mapping and melanoma, the London question is usually about report turnaround and the radiologist reading it — not whether the scan is available. Public provision for mole mapping and melanoma is competent but constrained by capacity. Private London clinics tend to have shorter diaries and longer appointment slots, so you get the same specialists with more time. For people who’ve been going round in circles with primary care, that first proper conversation is often what shifts things.
Once you’re in the private system for mole mapping and melanoma, the pace picks up noticeably. Consultant slots run to time, imaging is usually available in the same building or a short walk away, and the report comes back typed and detailed. It’s the coordination that tends to feel different — one person on the other end of the phone, not a switchboard. For mole mapping and melanoma specifically, the difference between a routine report and a sub-speciality read is where private care earns its keep.
There are a lot of consultants in London who can technically handle mole mapping and melanoma. Fewer who do it week in, week out for the exact question you’re bringing. We spend most of our time working out which is which — and being straight when a different test or a different specialist would serve you better. Everything runs to CQC, GMC and Royal College standards; the choice is about fit, not floor.